Recurrent Efficacy
In recurrent GBM,
A randomized trial showed Optune Gio™ monotherapy demonstrated efficacy comparable to that of chemotherapy*
Median OS was similar at 6.6 months with Optune Gio monotherapy and 6.0 months with physician's choice of chemotherapy1,*
Overall Survival1
Twice as many patients responded to Optune Gio vs physician’s choice of chemotherapy2
Therapy options were the physician's best choice for chemotherapy. The best available therapy was prescribed according to local practice and depending on prior treatment exposure.1
OS correlated with treatment usage in a subgroup analysis of patients treated with Optune Gio3,†
Subgroup analysis of patients receiving Optune Gio
- OS was significantly higher in patients who received Optune Gio for ≥18 hours per day (n=92) vs those who received therapy for <18 hours per day (n=28), 7.7 months vs 4.5 months, respectively3
- Median usage was 86% (range 41%-98%) of the time in each treatment month, translating into a mean use of 20.6 hours per day1
Learn how Optune Gio impacted quality of life for patients with recurrent GBM
†From a post hoc analysis.
GBM, glioblastoma; OS, overall survival.
References: 1. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192-2202. 2. Wong ET, Lok E, Swanson KD, et al. Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma. Cancer Med. 2014;3(3):592-602. 3. Kanner AA, Wong ET, Villano JL, Ram Z; EF-11 Investigators. Corrigendum to "Post hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice of chemotherapy" [Seminars in Oncology, Vol 41, No 5, Suppl 6, October 2014, ppS25-S34]. Semin Oncol. 2015;42(3):e56-e66.